Amerise biosciences Limited has filed its quarterly compliance certificate with BSE Limited for the quarter ended 31st March 2026, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated 06.04.2026, demonstrates the company's adherence to mandatory reporting obligations for listed entities.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting on dematerialization activities. Satellite Corporate Services Private Limited, serving as the company's Registrar & Share Transfer Agent, issued the compliance certificate confirming the status of physical share certificate processing during the reporting period.

Dematerialization Status

The certificate confirms that no physical share certificates were received for dematerialization during the quarter ended 31st March 2026. This indicates that all existing shareholders maintained their holdings in electronic format throughout Q4FY26, reflecting the widespread adoption of dematerialized trading among the company's investor base.

Satellite Corporate Services Private Limited, registered as Category-I Registrar to an Issue & Share Transfer Agent with registration number INR000003639, certified compliance with standard dematerialization procedures. The registrar confirmed that securities comprised in certificates are listed on stock exchanges and that proper verification and record-keeping protocols are maintained.

Corporate Information

Amerise Biosciences Limited, formerly known as Amradeep Industries Limited, operates under CIN L29199GJ1984PLC007195. The company is headquartered at 24, Laxmi Chambers, Navjeevan Press Road, opposite Old Gujarat High Court, Ahmedabad-380014. Albert Hines, serving as Director, signed the regulatory submission on behalf of the company.

The filing was simultaneously submitted to National Securities Depository Limited and Central Depository Services (India) Limited, ensuring comprehensive regulatory compliance across all relevant depositories. This quarterly certification process maintains transparency in the dematerialization framework and protects investor interests in electronic trading systems.

Amerise Biosciences Limited announced key leadership changes and approved quarterly financial results during its board meeting held on February 2, 2026. The meeting, which commenced at 03:45 PM and concluded at 04:15 PM at the company's registered office, addressed several important corporate matters.

Leadership Transition

The board approved the appointment of Mr. Albert Hines as Whole-time Director and Chief Financial Officer effective February 2, 2026. Simultaneously, the company accepted the resignation of Mr. Dinesh Rathod from the same positions on the same date.

New CFO Profile

Mr. Albert Hines brings relevant experience to his new role at Amerise Biosciences Limited. The 25-year-old executive has more than 3 years of experience in accounts and finance. According to the company's disclosure, Mr. Hines does not hold any shares in the company at the time of his appointment.

Resignation Details

Mr. Dinesh Rathod submitted his resignation citing personal commitments and pre-occupation with other work as the primary reasons for his departure. In his resignation letter dated February 2, 2026, Rathod expressed gratitude to the board members for their cooperation and assistance during his tenure as director.

Financial Results Approval

The board considered and approved the company's unaudited financial results for the quarter and nine months ended December 31, 2025. This approval was made in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The announcements were made pursuant to Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company, formerly known as Amradeep Industries Limited, trades on BSE with scrip code 531681 under the security ID AMERISE.